West China Journal of Stomatology ›› 2018, Vol. 36 ›› Issue (6): 686-690.doi: 10.7518/hxkq.2018.06.020
Previous Articles Next Articles
Xueqin Zhou1,2,Jun Ren1,2,Sen Yang1,2()
Received:
2018-01-11
Revised:
2018-07-09
Online:
2018-12-01
Published:
2018-12-12
Contact:
Sen Yang
E-mail:42831594@qq.com
Supported by:
CLC Number:
Xueqin Zhou,Jun Ren,Sen Yang. Relationship between thrombospondin-1 and the occurrence and development of oral and maxillofacial malignancy[J]. West China Journal of Stomatology, 2018, 36(6): 686-690.
Add to citation manager EndNote|Ris|BibTeX
[1] |
Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease[J]. Nat Med, 1995,1(1):27-30.
doi: 10.1038/nm0195-27 URL pmid: 7584949 |
[2] |
Weng TY, Huang SS, Yen MC , et al. A novel cancer thera-peutic using thrombospondin 1 in dendritic cells[J]. Mol Ther, 2014,22(2):292-302.
doi: 10.1038/mt.2013.236 URL pmid: 24127010 |
[3] | 张志愿, 俞光岩 . 口腔颌面外科学[M]. 7版. 北京: 人民卫生出版社, 2012: 281. |
Zhang ZY, Yu GY. Oral and maxillofacial surgery[M]. 7th ed. Beijing: People’s Medical Publishing House, 2012: 281. | |
[4] |
Schadler KL, Crosby EJ, Zhou AY , et al. Immunosurveil-lance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1[J]. Cancer Res, 2014,74(8):2171-2181.
doi: 10.1158/0008-5472.CAN-13-0094 URL pmid: 8980132210002224590059 |
[5] |
Amagasaki K, Sasaki A, Kato G , et al. Antisense-mediated reduction in thrombospondin-1 expression reduces cell moti-lity in malignant gliomacells[J]. Int J Cancer, 2001,94(4):508-512.
doi: 10.1002/ijc.1497 URL |
[6] |
Grutzmacher C, Park S, Zhao Y , et al. Aberrant production of extracellular matrix proteins and dysfunction in kidney endothelial cells with a short duration of diabetes[J]. Am J Physiol Renal Physiol, 2013,304(1):F19-F30.
doi: 10.1152/ajprenal.00036.2012 URL |
[7] |
Esemuede N, Lee T, Pierre-Paul D , et al. The role of throm-bospondin-1 in human disease1[J]. J Surg Res, 2004,122(1):135-142.
doi: 10.1016/j.jss.2004.05.015 URL pmid: 15522326 |
[8] | Roberts DD . Thrombospondins: from structure to therapeu-tics[J]. Cell Mol Life Sci, 2008,65(5):669-671. |
[9] |
Adams JC . Thrombospondin-1[J]. Int J Biochem Cell Biol, 1997,29(6):861-865.
doi: 10.1016/S1357-2725(96)00171-9 URL |
[10] |
Qian X, Tuszynski GP . Expression of thrombospondin-1 in cancer: a role in tumor progression[J]. Exp Biol Med, 1996,212(3):199-207.
doi: 10.3181/00379727-212-44008 URL pmid: 8677265 |
[11] |
Bornstein P . Thrombospondins: structure and regulation of expression[J]. FASEB, 1992,6(14):3290-3299.
doi: 10.1016/0014-4827(92)90067-I URL pmid: 8422970 |
[12] |
McCracken MN, Cha AC, Weissman IL . Molecular path-ways: activating T cells after cancer cell phagocytosis from blockade of CD47 “don’t eat me” signals[J]. Clin Cancer Res, 2015,21(16):3597-3601.
doi: 10.1158/1078-0432.CCR-14-2520 URL pmid: 26116271 |
[13] |
Jaiswal S, Chao MP, Majeti R , et al. Macrophages as media-tors of tumor immunosurveillance[J]. Trends Immunol, 2010,31(6):212-219.
doi: 10.1016/j.it.2010.04.001 URL pmid: 20452821 |
[14] |
Isenberg JS, Martin-Manso G, Maxhimer JB , et al. Regula-tion of nitric oxide signalling by thrombospondin 1: impli-cations for anti-angiogenictherapies[J]. Nat Rev Cancer, 2009,9(3):182-194.
doi: 10.1038/nrc2561 URL pmid: 19194382 |
[15] | Ren B, Yee KO, Lawler J , et al. Regulation of tumor angio-genesis by thrombospondin-1[J]. Biochim Biophys Acta, 2006,1765(2):178-188. |
[16] |
Watnick RS, Rodriguez RK, Wang S , et al. Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells[J]. Oncogene, 2015,34(22):2823-2835.
doi: 10.1038/onc.2014.228 URL pmid: 25109329 |
[17] |
Miyata Y, Sakai H . Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic pros-pects[J]. Int J Mol Sci, 2013,14(6):12249-12272.
doi: 10.3390/ijms140612249 URL pmid: 3709784 |
[18] |
Yap R . Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin pep-tide ABT-510: a complementation antiangiogenic strategy[J]. Clin Cancer Res, 2005,11(18):6678-6685.
doi: 10.1158/1078-0432.CCR-05-0621 URL pmid: 16166447 |
[19] |
Tao WY, Liang XS, Liu Y , et al. Decrease of let-7f in low-dose metronomic paclitaxel chemotherapy contributed to upregulation of thrombospondin-1 in breast cancer[J]. Int J Biol Sci, 2015,11(1):48-58.
doi: 10.7150/ijbs.9969 URL pmid: 25552929 |
[20] |
Rodriguez-Manzaneque JC, Lane TF, Ortega MA , et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor[J]. Proc Natl Acad Sci USA, 2001,98(22):12485-12490.
doi: 10.1073/pnas.171460498 URL |
[21] |
Fontana A, Filleur S, Guglielmi J , et al. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo[J]. Int J Cancer, 2005,116(5):686-691.
doi: 10.1002/ijc.20584 URL pmid: 15838828 |
[22] |
Rice AJ . Thrombospondin 1 protein expression relates to good prognostic indices in ductal carcinoma in situ of the breast[J]. J Clin Pathol, 2002,55(12):921-925.
doi: 10.1136/jcp.55.12.921 URL pmid: 539294 |
[23] |
Wang XJ, Yu JJ, Sreekumar A , et al. Autoantibody signatures in prostate cancer[J]. N Engl J Med, 2005,353(12):1224-1235.
doi: 10.1016/j.eururo.2005.12.066 URL pmid: 16177248 |
[24] | Dhanasekaran SM, Barrette TR, Ghosh D , et al. Delineation of prognostic biomarkers in prostate cancer[J]. Nature, 2001,412(6849):822-826. |
[25] | Luo J, Duggan DJ, Chen Y , et al. Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling[J]. Cancer Res, 2001,61(12):4683-4688. |
[26] | Bastian M, Steiner M, Schuff-Werner P . Expression of throm-bospondin-1 in prostate-derived cell lines[J]. Int J Mol Med, 2005,15(1):49-56. |
[27] |
Gustavsson H, Tesan T, Jennbacken K , et al. ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors[J]. BMC Cancer, 2010,10:288.
doi: 10.1186/1471-2407-10-288 URL pmid: 2894797 |
[28] |
Firlej V, Mathieu JR, Gilbert C , et al. Thrombospondin-1 triggers cell migration and development of advanced prostate tumors[J]. Cancer Res, 2011,71(24):7649-7658.
doi: 10.1158/0008-5472.CAN-11-0833 URL pmid: 22037878 |
[29] |
Yang F, Song L, Xing N , et al. AB170. Quercetin inhibits angiogenesis through thrombospondin-1 up-regulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo[J]. Oncol Rep, 2016,5(Suppl 1):1602-1610.
doi: 10.21037/tau.2016.s170 URL pmid: 26676551 |
[30] |
Rouanne M, Adam J, Goubar A , et al. Osteopontin and throm-bospondin-1 play opposite roles in promoting tumor aggres-siveness of primary resected non-small cell lung cancer[J]. BMC Cancer, 2016,16:483.
doi: 10.1186/s12885-016-2541-5 URL pmid: 4947364 |
[31] |
Yamaguchi M, Sugio K, Ondo K , et al. Reduced expression of thrombospondin-1 correlates with a poor prognosis in patients with non-small cell lung cancer[J]. Lung Cancer, 2002,36(2):143-150.
doi: 10.1016/S0169-5002(01)00470-6 URL pmid: 11955648 |
[32] |
Fleitas T, Martínez-Sales V, Vila V , et al. VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer[J]. Clin Transl Oncol, 2013,15(11):897-902.
doi: 10.1007/s12094-013-1020-6 URL pmid: 23463593 |
[33] |
Puri N, Pitman RT, Mulnix RE , et al. Non-small cell lung cancer is susceptible to induction of DNA damage responses and inhibition of angiogenesis by telomere overhang oli-gonucleotides[J]. Cancer Lett, 2014,343(1):14-23.
doi: 10.1016/j.canlet.2013.09.010 URL pmid: 24041868 |
[34] |
Laklai H, Laval S, Dumartin L , et al. Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 soma-tostatin receptor on pancreatic cancer[J]. Proc Natl Acad Sci USA, 2009,106(42):17769-17774.
doi: 10.1073/pnas.0908674106 URL pmid: 19805200 |
[35] | Kragh M, Quistorff B, Tenan M , et al. Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma[J]. Cancer Res, 2002,62(4):1191-1195. |
[36] |
Zhang J, Yang W, Zhao DY , et al. Correlation between TSP-1, TGF-β and PPAR-γ expression levels and gliomamicrovasculardensity[J]. Oncol Let, 2014,7(1):95-100.
doi: 10.3892/ol.2013.1650 URL pmid: 3861559 |
[37] |
Gaustad JV, Simonsen TG, Andersen LMK , et al. Throm-bospondin-1 domain-containing peptide properdistatin im-proves vascular function in human melanoma xenografts[J]. Microvasc Res, 2015,98:159-165.
doi: 10.1016/j.mvr.2014.02.005 URL |
[38] |
Bocci G, Fioravanti A, Orlandi P , et al. Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclinD1[J]. Neoplasia, 2012,14(9):833-845.
doi: 10.1593/neo.12772 URL pmid: 3459279 |
[39] |
Pour L, Svachova H, Adam Z , et al. Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma[J]. Neo-plasma, 2010,57(1):29-34.
doi: 10.4149/neo_2010_01_029 URL pmid: 19895169 |
[40] |
Hayashido Y, Nakashima M, Urabe K , et al. Role of stromal thrombospondin-1 in motility and proteolytic activity of oral squamous cell carcinoma cells[J]. Int J Mol Med, 2003,12(4):447-452.
doi: 10.3892/ijmm.12.4.447 URL pmid: 12964017 |
[41] |
Yao L, Zhao YL, Itoh S , et al. Thrombospondin-1 expression in oral squamous cell carcinomas: correlations with tumor vascularity, clinicopathological features and survival[J]. Oral Oncol, 2000,36(6):539-544.
doi: 10.1016/S1368-8375(00)00048-8 URL pmid: 11036248 |
[42] |
杨森, 唐休发, 郭丽娟 , 等. 黏液表皮样癌中TSP-1表达与肿瘤血管生成及其生物学行为的关系研究[J]. 四川大学学报(医学版), 2008,39(5):763-765.
doi: 10.3969/j.issn.1672-173X.2008.05.016 URL |
Yang S, Tang XF, Guo LJ , et al. Correlation between the expression of thrombospondin-1 and the angiogenesis in mucoepidermoid carcinoma[J]. J Sichuan Univ (Med Sci Ed), 2008,39(5):763-765.
doi: 10.3969/j.issn.1672-173X.2008.05.016 URL |
|
[43] |
Yang S, Wang XY, Guo LJ , et al. Correlation between the expression of thrombospondin-1 and neovascularization in mucoepidermoid carcinoma[J]. Chin Med J, 2008,121(19):1875-1881.
doi: 10.1016/j.ijom.2009.03.483 URL pmid: 19080117 |
[44] | 杨森, 李安, 郭丽娟 , 等. 唾液腺黏液表皮样癌组织中分化抑制因子-1和血小板反应蛋白-1的表达[J]. 华西口腔医学杂志, 2008,26(4):425-429. |
Yang S, Li A, Guo LJ , et al. The expression of inhibitor-1 of DNA binding/differentiation-1 and thrombospondin-1 in mucoepidermoid carcinoma of different malignant degree[J]. West Chin J Stomatol, 2008,26(4):425-429. | |
[45] |
Yang S, Guo LJ, Tang XF , et al. The alteration of Id-1 and TSP-1 expression in mucoepidermoid carcinoma associated with its clinical features and prognosis[J]. Int J Oral Maxil-lofac Surg, 2010,39(1):29-35.
doi: 10.1016/j.ijom.2009.10.004 URL pmid: 19906510 |
[46] | 龚仁国 . Id-1和TSP-1在唾液腺腺样囊性癌中的表达及意义[D]. 成都: 四川大学, 2007. |
Gong RG . Expression and significance of Id-1 and TSP-1 in human adenoid cystic carcinoma[D]. Chengdu: Sichuan University, 2007. | |
[47] |
Qian X, Tuszynski GP . Expression of thrombospondin-1 in cancer: a role in tumor progression[J]. Exp Biol Med, 1996,212(3):199-207.
doi: 10.3181/00379727-212-44008 URL pmid: 8677265 |
[48] |
Kaur S, Roberts DD . Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 sig-naling[J]. Int J Biochem Cell Biol, 2016,81(Pt A):184-194.
doi: 10.1016/j.biocel.2016.05.005 URL pmid: 27163531 |
[49] |
Denèfle T, Boullet H, Herbi L , et al. Thrombospondin-1 mimetic agonist peptides induce selective death in tumor cells: design, synjournal, and structure-activity relationship studies[J]. J Med Chem, 2016,59(18):8412-8421.
doi: 10.1021/acs.jmedchem.6b00781 URL pmid: 27526615 |
[50] |
Jeanne A, Boulagnon-Rombi C, Devy J , et al. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide[J]. Clin Exp Meta-stasis, 2016,33(7):637-649.
doi: 10.1007/s10585-016-9803-0 URL pmid: 27349907 |
[51] | Chawla A . Regulation of anti-angiogenicpedf through a tsp-1-cd36 pathway in prostate cancer[J/OL]. Disser Theses-Gradwork, 2013: 672[2017-12-27]. . |
[52] |
Streit M, Velasco P, Brown LF , et al. Over expression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous cell carcinomas[J]. Am J Pathol, 1999,155:441-452.
doi: 10.1016/S0002-9440(10)65140-1 URL pmid: 10433937 |
[53] |
Lindner DJ, Wu Y, Haney R , et al. Thrombospondin-1 expres-sion in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis[J]. Matrix Biol, 2013,32(2):123-132.
doi: 10.1016/j.matbio.2012.11.010 URL pmid: 3615071 |
[54] |
Ferdous T, Harada K, Kin T , et al. Efficacy of schedule-dependent metronomic S-1 chemotherapy in human oral squamous cell carcinoma cells[J]. Int J Oncol, 2013,43(1):271-279.
doi: 10.3892/ijo.2013.1950 URL pmid: 23695365 |
[55] |
Isenberg JS, Ridnour LA, Perruccio EM , et al. Thrombos-pondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner[J]. Proceed Natl Acad Sci, 2005,102(37):13141-13146.
doi: 10.1073/pnas.0502977102 URL |
[56] |
Miao WM, Seng WL, Duquette M , et al. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms[J]. Cancer Res, 2001,61(21):7830-7839.
doi: 10.1046/j.1523-5394.2001.96003.x URL pmid: 11691800 |
[57] |
Rofstad EK, Henriksen K, Galappathi K , et al. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts[J]. Cancer Res, 2003,63(14):4055-4061.
doi: 10.1016/S0165-4608(03)00013-X URL pmid: 12874006 |
[58] |
Jeanne A, Schneider C, Martiny L , et al. Original insights on thrombospondin-1-related antireceptor strategies in cancer[J]. Front Pharmacol, 2015,6:252.
doi: 10.3389/fphar.2015.00252 URL pmid: 4625054 |
[1] | XING Ru-dong1, CHANG Shi-min2,DUAN Yu-qin3,ZHANG Fang-ming2,DONG Fu-sheng4. Examination of Serum Hyaluronic Acid Level in Patients with Oral and Maxillofacial Malignancy [J]. West China Journal of Stomatology, 2004, 22(04): 309-311. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||